tranexamic acid has been researched along with Venous Thromboembolism in 87 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 9.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| "Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 9.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
| "Tranexamic acid (TXA) is poorly studied in patients with bone and musculoskeletal sarcoma due to perceived increased risk of venous thromboembolism (VTE)." | 8.31 | Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery. ( Andrews, NA; Crowley, B; Hess, MC; Howie, C; McGwin, G; Siegel, H; Singh, NP, 2023) |
| "This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 8.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
| "In hospitalized patients with hemoptysis, the risk of VTE was found to be independently associated with the administration of tranexamic acid (TXA), the presence of D-dimer, and the Charlson Comorbidity Index (CCI) score (p<0." | 8.31 | Does the use of tranexamic acid increase the risk of VTE in patients with hemoptysis? ( Dong, YY; Fang, SY; Zhang, JL, 2023) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 7.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "To assess whether use of tranexamic acid is associated with an increased risk of venous thromboembolism (VTE)." | 7.75 | The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. ( Alfredsson, L; Kieler, H; Seaman, H; Sundström, A, 2009) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 7.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "The aim of the present study was to assess the incidence of and risk factors for thromboembolic events-including assessment of the intraoperative use of tranexamic acid and postoperative use of chemical thromboprophylaxis-in patients undergoing operative treatment of primary bone or soft-tissue sarcoma or oligometastatic bone disease." | 5.69 | Incidence of and Risk Factors for Thromboembolism After Endoprosthetic Reconstruction in Musculoskeletal Oncology Patients. ( Forsberg, JA; Levin, AS; LiBrizzi, CL; Morris, CD; Sabharwal, S, 2023) |
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 5.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| "In our series, topical and intravenous TXA were equally safe when used in patients with a history of CAD and coronary stents in comparison with the control cohort." | 5.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 5.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| " Tranexamic acid (TXA) is most commonly given as a single preoperative dose only and is often withheld from patients with a history of thromboembolic disease as they are perceived to be "high-risk" with respect to postoperative venous thromboembolism (VTE)." | 5.41 | Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total hip arthroplasty: results of a randomized controlled trial (TRAC-24). ( Bell, J; Benson, G; Beverland, D; Bryce, L; Campbell, C; Dorman, A; Gardner, E; Hill, JC; Hogg, R; Magill, P; Martin, U; McFarland, M, 2021) |
| "Our study showed no clinical benefit or disadvantage to closed suction drainage in anterior hip arthroplasty with the concomitant use of tranexamic acid for surgical hemostasis and aspirin for venous thromboembolism prophylaxis." | 5.22 | Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial. ( Barksdale, LC; Calvo, C; McNamara, CA; Patel, PD; Suarez, JC; Szubski, CR, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug associated with improved survival among trauma patients with hemorrhage." | 5.12 | The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis. ( Almuwallad, A; Cole, E; Davenport, R; Perkins, Z; Ross, J, 2021) |
| "Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 5.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
| "In hospitalized patients with hemoptysis, the risk of VTE was found to be independently associated with the administration of tranexamic acid (TXA), the presence of D-dimer, and the Charlson Comorbidity Index (CCI) score (p<0." | 4.31 | Does the use of tranexamic acid increase the risk of VTE in patients with hemoptysis? ( Dong, YY; Fang, SY; Zhang, JL, 2023) |
| "Nationally, a higher percentage of patients received tranexamic acid without a postpartum hemorrhage diagnosis compared with previous studies, and the western region of the United States had an overall increased use of tranexamic acid during delivery compared with previous years." | 4.31 | An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021. ( Ahmadzia, HK; Dazelle, WDH; Litman, EA; Sterling, EK, 2023) |
| "This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 4.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
| "Tranexamic acid (TXA) is poorly studied in patients with bone and musculoskeletal sarcoma due to perceived increased risk of venous thromboembolism (VTE)." | 4.31 | Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery. ( Andrews, NA; Crowley, B; Hess, MC; Howie, C; McGwin, G; Siegel, H; Singh, NP, 2023) |
| "To determine if there is a significant association between administration of tranexamic acid (TXA) in severely bleeding, injured patients, and venous thromboembolism (VTE), myocardial infarction (MI), or cerebrovascular accident (CVA)." | 4.02 | The incidence of venous thromboembolic events in trauma patients after tranexamic acid administration: an EAST multicenter study. ( Albertson, S; Allen, R; Bernard, A; Bugaev, N; Carrick, M; Carter, K; Chang, G; Cullinane, DC; Estroff, J; Grigorian, A; Hamrick, A; Harrell, K; Hazelton, JP; Jain, G; Jeyamurugan, K; Kovar, A; Kutcher, M; Lee, A; Luo-Owen, X; Mount, M; Nahmias, J; Pascual, J; Quattrone, M; Quispe, JC; Ratnasekera, A; Rivas, L; Rodriguez, C; Sarani, B; Selevany, M; Smith, SR; Spalding, C; Sparks, A; Tamburrini, D; Tororello, G; Turay, D; Urban, S; Vella, M; Warner, A; Weinberger, J; Wright, F, 2021) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 3.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "Geriatric hip fracture patients are particularly susceptible to blood loss and venous thromboembolism (VTE) during hemiarthroplasty, yet relatively few studies have examined the safety and efficacy of tranexamic acid (TXA) in these patients." | 3.91 | Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study. ( Chen, G; Hu, Q; Huang, Q; Pei, F; Xie, J; Zhou, Z, 2019) |
| " Tranexamic acid administration was an independent risk factor for venous thromboembolism (odds ratio, 2." | 3.88 | Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events. ( Bradley, MJ; Elster, EA; Johnston, LR; Rodriguez, CJ, 2018) |
| "Tranexamic acid demonstrated a significant benefit in decreasing change in hemoglobin as well as the need for blood transfusion with no increase in the risk of venous thromboembolism in patients undergoing total knee or total hip replacement." | 3.85 | Impact of Tranexamic Acid in Total Knee and Total Hip Replacement. ( Boyle, JA; Soric, MM, 2017) |
| "Sequential cohort study analysing hemoglobin titers, transfusion rates, and the occurrence of venous thromboembolism in patients undergoing hip and knee replacements with and without the administration of tranexamic acid at the time of induction." | 3.78 | The routine use of tranexamic acid in hip and knee replacements. ( Chegini, S; Kucheria, R; Lobban, C; Panchmatia, JR; Shah, G; Smallman, JM; Stapleton, C, 2012) |
| "To assess whether use of tranexamic acid is associated with an increased risk of venous thromboembolism (VTE)." | 3.75 | The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. ( Alfredsson, L; Kieler, H; Seaman, H; Sundström, A, 2009) |
| "Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery." | 3.30 | Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. ( Wang, CC; Wu, T; Zhang, GQ; Zhang, LT; Zhou, LB, 2023) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic effective in reducing blood loss in orthopedic surgery." | 3.11 | Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery. ( Clohisy, JCF; Dafrawy, MHE; Frazier, E; Kelly, MP; Lenke, LG; Wolfe, RC, 2022) |
| "Tranexamic acid (TXA) is a standard component of Tactical Combat Casualty Care." | 3.01 | A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care. ( Ho, JW; Keeney-Bonthrone, TP; Lozano, R; Ruf, AC; Russo, RM; Strayve, D; Zakaluzny, SA, 2023) |
| "Tranexamic acid (TXA) has drawn growing interest over the last decade for its benefit in optimizing post-operative bleeding, yet its role in bariatric surgery is poorly understood." | 3.01 | Role of Tranexamic Acid (TXA) in Preventing Bleeding Following Sleeve Gastrectomy: a Systematic Review and Meta-analysis. ( Karmali, S; Koloszvari, N; Kung, J; Mocanu, V; Neville, A; Verhoeff, K; Walsh, C; Wilson, H, 2023) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic that has been shown to reduce surgical blood losses; however, its use in burn surgery is not well established." | 3.01 | Tranexamic acid in burn surgery: A systematic review and meta-analysis. ( Boctor, MJ; Fijany, AJ; Gandhi, RR; Givechian, KB; Olsson, SE; Pekarev, M; Zago, I, 2023) |
| "Tranexamic acid (TXA) has long been used to reduce blood loss associated with total knee arthroplasty (TKA)." | 2.90 | Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. ( Bernaitis, N; Dare, W; King, L; Randle, R, 2019) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| " combined with topical administration of TXA decreases postoperative blood loss and transfusion rates after THA." | 2.84 | Intravenous Combined with Topical Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. ( Kang, PD; Pei, FX; Shen, B; Si, HB; Yang, J; Zeng, Y; Zhou, ZK, 2017) |
| "Tranexamic acid (TXA) has been widely used for bleeding reduction in spinal surgery." | 2.82 | Optimal administration strategies of tranexamic acid to minimize blood loss during spinal surgery: results of a Bayesian network meta-analysis. ( Cao, Z; Guo, J; Li, Q; Li, Y; Wu, J, 2022) |
| "Fixed dose of TXA for patients undergoing simultaneous bilateral TKAs was effective and safe in reducing total blood loss and allogeneic blood transfusion needs without any additional thromboembolic risk." | 2.82 | Effectiveness and Safety of Fixed-Dose Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Randomized Double-Blind Controlled Trial. ( Cao, X; Chen, X; Guo, K; Yang, C; Zhu, J; Zhu, Q, 2016) |
| "Tranexamic acid is a safe and effective treatment modality, and consideration should be given to use multiple doses and combine different modes of administration." | 2.66 | Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2). ( Mastel, MS; van der Merwe, JM, 2020) |
| " Other severe drug-related adverse events occurred very rarely (0." | 2.58 | Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. ( Franchini, M; Liumbruno, GM; Mannucci, PM; Marano, G; Marietta, M; Mengoli, C; Pupella, S; Vaglio, S, 2018) |
| " Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective." | 2.52 | Tranexamic Acid in Hip and Knee Arthroplasty. ( Melvin, JS; Sierra, RJ; Stryker, LS, 2015) |
| " Its application is not associated with increased risk of venous thromboembolisms or other adverse events." | 2.49 | A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. ( Chen, C; Chen, H; Huang, W; Liu, Q; Tan, J, 2013) |
| "Tranexamic acid (TXA) has been proven to reduce perioperative blood loss and the incidence of allogeneic blood transfusion in total joint arthroplasty (TJA)." | 1.72 | Combination effect of intraoperative and postoperative intravenous tranexamic acid in hip hemiarthroplasty. A propensity score matched analysis. ( Chang, Q; Li, C; Li, Y; Zhang, W, 2022) |
| "To examine UK haemophilia centre registration patterns and current practice for UBD patients." | 1.62 | Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. ( Desborough, M; Downes, K; Evans, G; Gidley, G; Lowe, G; MacDonald, S; O'Donnell, JS; Obaji, S; Palmer, B; Pinto, F; Thomas, W, 2021) |
| "In our series, topical and intravenous TXA were equally safe when used in patients with a history of CAD and coronary stents in comparison with the control cohort." | 1.62 | Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. ( Rozell, JC; Schwarzkopf, R; Sharan, M; Tang, A; Waren, D; Zak, SG, 2021) |
| "Ninety-five patients received TXA for traumatic injuries, 42." | 1.62 | Unjustified Administration in Liberal Use of Tranexamic Acid in Trauma Resuscitation. ( Adams, CA; Jikaria, N; Kheirbek, T; Lueckel, SN; Martin, TJ; Monaghan, SF; Murray, B; Stephen, AH, 2021) |
| " We hypothesized that extending a protocol for TXA administration into the prehospital aeromedical setting would improve outcomes while maintaining a similar safety profile to TXA dosed in the emergency department (ED)." | 1.51 | Prehospital Tranexamic Acid Administration During Aeromedical Transport After Injury. ( Boudreau, RM; Day, GM; Deshpande, KK; Goodman, MD; Harger, N; Hinckley, WR; Makley, AT; Pritts, TA, 2019) |
| "Tranexamic acid was not used perioperatively." | 1.46 | Prevalence of Venous Thromboembolic Events Is Low in Asians After Total Knee Arthroplasty Without Chemoprophylaxis. ( Bin Abd Razak, HR; Binte Abd Razak, NF; Tan, HA, 2017) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 1.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| "The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.15) | 29.6817 |
| 2010's | 42 (48.28) | 24.3611 |
| 2020's | 44 (50.57) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, CX | 1 |
| Yao, YF | 1 |
| Lv, H | 1 |
| Cheng, L | 1 |
| Jing, JH | 1 |
| Murao, S | 1 |
| Nakata, H | 1 |
| Roberts, I | 1 |
| Yamakawa, K | 1 |
| Kim, CH | 1 |
| Lim, EJ | 1 |
| Kim, S | 1 |
| Kim, JW | 1 |
| Okuzu, Y | 1 |
| Goto, K | 1 |
| Kuroda, Y | 1 |
| Kawai, T | 1 |
| Matsuda, S | 1 |
| Fowler, H | 1 |
| Law, J | 1 |
| Tham, SM | 1 |
| Gunaravi, SA | 1 |
| Houghton, N | 1 |
| Clifford, RE | 1 |
| Fok, M | 1 |
| Barker, JA | 1 |
| Vimalachandran, D | 1 |
| Tan, G | 1 |
| Xie, LW | 1 |
| Yi, SJ | 1 |
| Chen, Y | 1 |
| Liu, X | 1 |
| Zhang, H | 1 |
| Clohisy, JCF | 1 |
| Lenke, LG | 1 |
| Dafrawy, MHE | 1 |
| Wolfe, RC | 1 |
| Frazier, E | 1 |
| Kelly, MP | 1 |
| Cao, Z | 1 |
| Li, Q | 2 |
| Guo, J | 1 |
| Li, Y | 2 |
| Wu, J | 1 |
| Li, C | 1 |
| Zhang, W | 1 |
| Chang, Q | 1 |
| Brito, RM | 1 |
| Oliveira, CMB | 1 |
| Moura, ECR | 1 |
| Campelo, GP | 1 |
| Lima, RC | 1 |
| Fe, CSM | 1 |
| Sousa, TM | 1 |
| Oliveira, EJSG | 1 |
| Dibai Filho, AV | 1 |
| Leal, PDC | 1 |
| Russo, RM | 1 |
| Lozano, R | 1 |
| Ruf, AC | 1 |
| Ho, JW | 1 |
| Strayve, D | 1 |
| Zakaluzny, SA | 1 |
| Keeney-Bonthrone, TP | 1 |
| Zhou, LB | 1 |
| Wang, CC | 1 |
| Zhang, LT | 1 |
| Wu, T | 1 |
| Zhang, GQ | 1 |
| Sterling, EK | 1 |
| Litman, EA | 1 |
| Dazelle, WDH | 1 |
| Ahmadzia, HK | 2 |
| Mocanu, V | 1 |
| Wilson, H | 1 |
| Verhoeff, K | 1 |
| Kung, J | 1 |
| Walsh, C | 1 |
| Koloszvari, N | 1 |
| Neville, A | 1 |
| Karmali, S | 1 |
| Fijany, AJ | 1 |
| Givechian, KB | 1 |
| Zago, I | 1 |
| Olsson, SE | 1 |
| Boctor, MJ | 1 |
| Gandhi, RR | 1 |
| Pekarev, M | 1 |
| Ye, S | 1 |
| Chen, M | 1 |
| Luo, Y | 1 |
| Zhao, C | 1 |
| Kang, P | 2 |
| Sabharwal, S | 1 |
| LiBrizzi, CL | 1 |
| Forsberg, JA | 1 |
| Morris, CD | 1 |
| Levin, AS | 1 |
| Zhang, JL | 1 |
| Dong, YY | 1 |
| Fang, SY | 1 |
| Knowlton, LM | 1 |
| Arnow, K | 1 |
| Trickey, AW | 1 |
| Sauaia, A | 1 |
| Knudson, MM | 1 |
| Zhang, Q | 1 |
| Zhao, L | 1 |
| Yu, Z | 1 |
| Guo, JJ | 1 |
| Hess, MC | 1 |
| Andrews, NA | 1 |
| Crowley, B | 1 |
| Singh, NP | 1 |
| Howie, C | 1 |
| McGwin, G | 1 |
| Siegel, H | 1 |
| Eisinger, EC | 1 |
| Forsythe, L | 1 |
| Joergensen, S | 1 |
| Murali, S | 1 |
| Cannon, JW | 1 |
| Reilly, PM | 1 |
| Kim, PK | 1 |
| Kaufman, EJ | 1 |
| Jakowenko, ND | 1 |
| Seelhammer, TG | 1 |
| Nabzdyk, CGS | 1 |
| Macielak, RJ | 1 |
| Nei, SD | 1 |
| Kalvelage, EL | 1 |
| Wieruszewski, PM | 1 |
| Xin, WQ | 1 |
| Gao, YL | 1 |
| Shen, J | 1 |
| Yang, XY | 1 |
| King, L | 1 |
| Randle, R | 1 |
| Dare, W | 1 |
| Bernaitis, N | 1 |
| Pathan, S | 1 |
| Cruz, JE | 1 |
| Curtin, P | 1 |
| Hines, JT | 1 |
| Petis, SM | 1 |
| Amundson, AW | 2 |
| Pagnano, MW | 2 |
| Sierra, RJ | 3 |
| Abdel, MP | 2 |
| Meizoso, JP | 1 |
| Namias, N | 1 |
| Proctor, KG | 1 |
| Leeman, M | 1 |
| Huisbrink, J | 1 |
| Wijnand, JMA | 1 |
| Biter, LU | 1 |
| Verbrugge, SJC | 1 |
| Dunkelgrun, M | 1 |
| Apers, JA | 1 |
| Geddes, J | 1 |
| McConaghie, G | 1 |
| van der Merwe, JM | 1 |
| Mastel, MS | 1 |
| Myers, SP | 2 |
| Neal, MD | 2 |
| Walsh, M | 1 |
| Grisoli, A | 1 |
| Zackariya, N | 1 |
| Thomas, AV | 1 |
| Sualeh, A | 1 |
| Walker, PF | 1 |
| Bozzay, JD | 1 |
| Johnston, LR | 2 |
| Elster, EA | 2 |
| Rodriguez, CJ | 2 |
| Bradley, MJ | 2 |
| Hynds, EB | 1 |
| Amdur, RL | 1 |
| Gimovsky, AC | 1 |
| James, AH | 1 |
| Luban, NLC | 1 |
| Kheirbek, T | 1 |
| Jikaria, N | 1 |
| Murray, B | 1 |
| Martin, TJ | 1 |
| Lueckel, SN | 1 |
| Stephen, AH | 1 |
| Monaghan, SF | 1 |
| Adams, CA | 1 |
| Rivas, L | 1 |
| Estroff, J | 1 |
| Sparks, A | 1 |
| Nahmias, J | 1 |
| Allen, R | 1 |
| Smith, SR | 1 |
| Kutcher, M | 1 |
| Carter, K | 1 |
| Grigorian, A | 1 |
| Albertson, S | 1 |
| Turay, D | 1 |
| Quispe, JC | 1 |
| Luo-Owen, X | 1 |
| Vella, M | 1 |
| Pascual, J | 1 |
| Tororello, G | 1 |
| Quattrone, M | 1 |
| Bernard, A | 1 |
| Ratnasekera, A | 1 |
| Lee, A | 1 |
| Tamburrini, D | 1 |
| Rodriguez, C | 1 |
| Harrell, K | 1 |
| Jeyamurugan, K | 1 |
| Bugaev, N | 1 |
| Warner, A | 1 |
| Weinberger, J | 1 |
| Hazelton, JP | 1 |
| Selevany, M | 1 |
| Wright, F | 1 |
| Kovar, A | 1 |
| Urban, S | 1 |
| Hamrick, A | 1 |
| Mount, M | 1 |
| Carrick, M | 1 |
| Cullinane, DC | 1 |
| Chang, G | 1 |
| Jain, G | 1 |
| Spalding, C | 1 |
| Sarani, B | 1 |
| Almuwallad, A | 1 |
| Cole, E | 1 |
| Ross, J | 1 |
| Perkins, Z | 1 |
| Davenport, R | 1 |
| Varady, NH | 1 |
| Chen, AF | 2 |
| Drayer, NJ | 1 |
| Ready, J | 1 |
| Lozano-Calderon, SA | 1 |
| Hayden, BL | 1 |
| Zak, SG | 1 |
| Tang, A | 1 |
| Sharan, M | 1 |
| Waren, D | 1 |
| Rozell, JC | 1 |
| Schwarzkopf, R | 1 |
| Jeschke, E | 1 |
| Citak, M | 2 |
| Halder, AM | 1 |
| Heller, KD | 1 |
| Niethard, FU | 1 |
| Schräder, P | 1 |
| Zacher, J | 1 |
| Leicht, H | 1 |
| Malzahn, J | 1 |
| Günster, C | 1 |
| Gehrke, T | 2 |
| Magill, P | 1 |
| Hill, JC | 1 |
| Bryce, L | 1 |
| Martin, U | 1 |
| Dorman, A | 1 |
| Hogg, R | 1 |
| Campbell, C | 1 |
| Gardner, E | 1 |
| McFarland, M | 1 |
| Bell, J | 1 |
| Benson, G | 1 |
| Beverland, D | 1 |
| Levent, A | 1 |
| Kose, O | 1 |
| Linke, P | 1 |
| Thomas, W | 1 |
| Downes, K | 1 |
| Evans, G | 1 |
| Gidley, G | 1 |
| Lowe, G | 1 |
| MacDonald, S | 1 |
| Obaji, S | 1 |
| O'Donnell, JS | 1 |
| Palmer, B | 1 |
| Pinto, F | 1 |
| Desborough, M | 1 |
| Goh, GS | 1 |
| D'Amore, T | 1 |
| Lonner, JH | 1 |
| Fillingham, YA | 1 |
| Klok, FA | 1 |
| Schreiber, K | 1 |
| Stach, K | 1 |
| Ageno, W | 1 |
| Middeldorp, S | 2 |
| Eichinger, S | 1 |
| Delluc, A | 1 |
| Blondon, M | 1 |
| Ay, C | 1 |
| Baskaran, D | 1 |
| Rahman, S | 1 |
| Salmasi, Y | 1 |
| Froghi, S | 1 |
| Berber, O | 1 |
| George, M | 1 |
| Etchill, EW | 1 |
| Fang, R | 1 |
| Haut, ER | 1 |
| Boonyawat, K | 1 |
| O'Brien, SH | 1 |
| Bates, SM | 1 |
| Franchini, M | 1 |
| Mengoli, C | 1 |
| Marietta, M | 1 |
| Marano, G | 1 |
| Vaglio, S | 1 |
| Pupella, S | 1 |
| Mannucci, PM | 1 |
| Liumbruno, GM | 1 |
| Thorne, JG | 1 |
| James, PD | 1 |
| Reid, RL | 1 |
| Karampinas, PK | 1 |
| Megaloikonomos, PD | 1 |
| Lampropoulou-Adamidou, K | 1 |
| Papadelis, EG | 1 |
| Mavrogenis, AF | 1 |
| Vlamis, JA | 1 |
| Pneumaticos, SG | 1 |
| Kutcher, ME | 1 |
| Rosengart, MR | 1 |
| Sperry, JL | 1 |
| Peitzman, AB | 1 |
| Brown, JB | 1 |
| Dastrup, A | 1 |
| Pottegård, A | 1 |
| Hallas, J | 1 |
| Overgaard, S | 1 |
| Boudreau, RM | 1 |
| Deshpande, KK | 1 |
| Day, GM | 1 |
| Hinckley, WR | 1 |
| Harger, N | 1 |
| Pritts, TA | 1 |
| Makley, AT | 1 |
| Goodman, MD | 1 |
| Sun, Q | 1 |
| Li, J | 1 |
| Chen, J | 1 |
| Zheng, C | 1 |
| Liu, C | 1 |
| Jia, Y | 1 |
| Gombár, C | 1 |
| Gálity, H | 1 |
| Bácsi, M | 1 |
| Sisák, K | 1 |
| Spitler, CA | 1 |
| Row, ER | 1 |
| Gardner, WE | 1 |
| Swafford, RE | 1 |
| Hankins, MJ | 1 |
| Nowotarski, PJ | 1 |
| Kiner, DW | 1 |
| Bistervels, IM | 1 |
| Scheres, LJJ | 1 |
| Hamulyák, EN | 1 |
| Xie, J | 4 |
| Zhang, S | 1 |
| Chen, G | 2 |
| Xu, H | 1 |
| Zhou, Z | 3 |
| Pei, F | 4 |
| Hu, Q | 1 |
| Huang, Q | 2 |
| Riaz, O | 1 |
| Aqil, A | 1 |
| Asmar, S | 1 |
| Vanker, R | 1 |
| Hahnel, J | 1 |
| Brew, C | 1 |
| Grogan, R | 1 |
| Radcliffe, G | 1 |
| Ko, BS | 1 |
| Cho, KJ | 1 |
| Kim, YT | 1 |
| Park, JW | 1 |
| Kim, NC | 1 |
| Tan, J | 1 |
| Chen, H | 1 |
| Liu, Q | 1 |
| Chen, C | 1 |
| Huang, W | 1 |
| Chang, CH | 1 |
| Chang, Y | 1 |
| Chen, DW | 1 |
| Ueng, SW | 1 |
| Lee, MS | 1 |
| Jang, B | 1 |
| Kao, M | 1 |
| Bohm, MT | 1 |
| Harris, IA | 1 |
| Chen, DB | 1 |
| MacDessi, SJ | 1 |
| Duncan, CM | 1 |
| Gillette, BP | 1 |
| Jacob, AK | 1 |
| Sanchez-Sotelo, J | 1 |
| Smith, HM | 1 |
| Harvin, JA | 1 |
| Peirce, CA | 1 |
| Mims, MM | 1 |
| Hudson, JA | 1 |
| Podbielski, JM | 1 |
| Wade, CE | 1 |
| Holcomb, JB | 1 |
| Cotton, BA | 1 |
| Ma, J | 2 |
| Shen, B | 2 |
| Yang, J | 2 |
| Formby, PM | 1 |
| Pickett, AM | 1 |
| Van Blarcum, GS | 1 |
| Mack, AW | 1 |
| Newman, MT | 1 |
| Melvin, JS | 1 |
| Stryker, LS | 1 |
| Boyle, JA | 1 |
| Soric, MM | 1 |
| Heller, S | 1 |
| Secrist, E | 1 |
| Shahi, A | 1 |
| Parvizi, J | 1 |
| Suarez, JC | 1 |
| McNamara, CA | 1 |
| Barksdale, LC | 1 |
| Calvo, C | 1 |
| Szubski, CR | 1 |
| Patel, PD | 1 |
| Chen, X | 1 |
| Cao, X | 1 |
| Yang, C | 1 |
| Guo, K | 1 |
| Zhu, Q | 1 |
| Zhu, J | 1 |
| Bonilla, GA | 1 |
| Gutierrez, C | 1 |
| Bautista, MP | 1 |
| Llinas, AM | 1 |
| Monsalvo, DJ | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Spitzer, AI | 1 |
| Spanyer, J | 1 |
| Patel, J | 1 |
| Emberton, E | 1 |
| Smith, LS | 1 |
| Malkani, AL | 1 |
| Bin Abd Razak, HR | 1 |
| Binte Abd Razak, NF | 1 |
| Tan, HA | 1 |
| Zeng, Y | 1 |
| Si, HB | 1 |
| Zhou, ZK | 1 |
| Kang, PD | 1 |
| Pei, FX | 1 |
| Yue, C | 1 |
| Sabbag, OD | 1 |
| Larson, DR | 1 |
| Lee, SY | 1 |
| Chong, S | 1 |
| Balasubramanian, D | 1 |
| Na, YG | 1 |
| Kim, TK | 1 |
| Sundström, A | 1 |
| Seaman, H | 1 |
| Kieler, H | 1 |
| Alfredsson, L | 1 |
| Lee, SH | 1 |
| Cho, KY | 1 |
| Khurana, S | 1 |
| Kim, KI | 1 |
| Panchmatia, JR | 1 |
| Chegini, S | 1 |
| Lobban, C | 1 |
| Shah, G | 1 |
| Stapleton, C | 1 |
| Smallman, JM | 1 |
| Kucheria, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238] | Phase 2 | 130 participants (Anticipated) | Interventional | 2023-04-12 | Recruiting | ||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408] | Phase 4 | 128 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| [NCT02644473] | Phase 4 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Study did not receive IRB approval, so did not start) | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| Analgesic Efficacy of Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Trial to Compare Postoperative Clinical Outcomes[NCT02908711] | Phase 4 | 50 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Analgesic Efficacy of Quadaratus Lumborum Block (QLB) for Laparoscopic Colectomy Surgery: A Prospective Observational Case Control Trial to Evaluate Clinical Outcomes[NCT03017638] | 14 participants (Actual) | Observational | 2017-02-27 | Completed | |||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 2046 |
| Standard of Care/Control | 1596 |
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| High Dose/Study Group | 2 |
| Standard of Care/Control | 3 |
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
| Intervention | mL (Mean) |
|---|---|
| High Dose/Study Group | 1259 |
| Standard of Care/Control | 935 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
18 reviews available for tranexamic acid and Venous Thromboembolism
| Article | Year |
|---|---|
Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Hemorrhage; Humans; Risk Assessment; Seizures; Str | 2021 |
The effect of antifibrinolytic agents in periacetabular osteotomy: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Osteotomy; Tranexamic Acid | 2022 |
Impact on blood loss and transfusion rates following administration of tranexamic acid in major oncological abdominal and pelvic surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Pelvic Neoplasms; Tranexamic Acid; Venous Thr | 2022 |
Optimal administration strategies of tranexamic acid to minimize blood loss during spinal surgery: results of a Bayesian network meta-analysis.
Topics: Antifibrinolytic Agents; Bayes Theorem; Blood Loss, Surgical; Humans; Network Meta-Analysis; Tranexa | 2022 |
A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Venous Thromboembolism; Venous Thrombo | 2023 |
Role of Tranexamic Acid (TXA) in Preventing Bleeding Following Sleeve Gastrectomy: a Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Gastrectomy; Humans; | 2023 |
Tranexamic acid in burn surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Burns; Humans; Tranexamic Acid; Venous Thromboembolis | 2023 |
Intravenous tranexamic acid reduces blood transfusions in revision total hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2019 |
Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2).
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgi | 2020 |
The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Randomized Controlled Trial | 2021 |
Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Contraceptives, Oral; Expert Testimon | 2017 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Blood Loss, Surgical; Female; Humans; Male; Orthopedic Procedures; Rand | 2018 |
Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Anemia; Antifibrinolytic Agents; Arthroplasty, | 2019 |
Sex matters: Practice 5P's when treating young women with venous thromboembolism.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low- | 2019 |
Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood | 2013 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2015 |
19 trials available for tranexamic acid and Venous Thromboembolism
| Article | Year |
|---|---|
Efficacy and Safety of Postoperative Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2021 |
Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Prospective Studies; Seizures; Tranexa | 2022 |
Tranexamic acid effects in postoperative bleeding outcomes in laparoscopic sleeve gastrectomy: a controlled study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Gastrectomy; | 2022 |
Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dalt | 2023 |
Comparative study of carbazochrome sodium sulfonate and tranexamic acid in reducing blood loss and inflammatory response following direct anterior total hip arthroplasty: a prospective randomized controlled trial.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgi | 2023 |
Incidence of and Risk Factors for Thromboembolism After Endoprosthetic Reconstruction in Musculoskeletal Oncology Patients.
Topics: Adult; Aged; Anticoagulants; Bone Diseases; Child; Humans; Incidence; Middle Aged; Prospective Studi | 2023 |
Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study.
Topics: Administration, Intravenous; Adult; Anticoagulants; Antifibrinolytic Agents; Arthritis; Arthroplasty | 2023 |
Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2019 |
Trial protocol: preoperative administration of tranexamic acid in sleeve gastrectomy (PATAS) to reduce haemorrhage rates. A randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Gastrectomy; Humans; Postoperative Hemorrhage; | 2020 |
Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total hip arthroplasty: results of a randomized controlled trial (TRAC-24).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthropla | 2021 |
Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2019 |
Tranexamic Acid Use in Open Reduction and Internal Fixation of Fractures of the Pelvis, Acetabulum, and Proximal Femur: A Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Femoral Fractures; | 2019 |
The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hospita | 2015 |
Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2016 |
Effectiveness and Safety of Fixed-Dose Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Randomized Double-Blind Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Intravenous Combined with Topical Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthro | 2017 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
What is the Ideal Route of Administration of Tranexamic Acid in TKA? A Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2017 |
Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2013 |
50 other studies available for tranexamic acid and Venous Thromboembolism
| Article | Year |
|---|---|
Closed suction drainage is not beneficial in hybrid total hip arthroplasty with intra-articular administration of tranexamic acid: a propensity score-matched cohort study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Cohort Studies; Human | 2022 |
The efficacy and safety of intravenous tranexamic acid on blood loss during total ankle replacement: a retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, | 2022 |
Combination effect of intraoperative and postoperative intravenous tranexamic acid in hip hemiarthroplasty. A propensity score matched analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiarthroplasty; Hum | 2022 |
An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021.
Topics: Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy; Retros | 2023 |
Does the use of tranexamic acid increase the risk of VTE in patients with hemoptysis?
Topics: Hemoptysis; Humans; Patients; Risk Factors; Tranexamic Acid; Venous Thromboembolism | 2023 |
Does tranexamic acid increase venous thromboembolism risk among trauma patients? A prospective multicenter analysis across 17 level I trauma centers.
Topics: Adolescent; Adult; Humans; Prospective Studies; Pulmonary Embolism; Tranexamic Acid; Trauma Centers; | 2023 |
Intravenous tranexamic acid decreases intraoperative transfusion requirements and does not increase incidence of symptomatic venous thromboembolic events in musculoskeletal sarcoma surgery.
Topics: Adult; Humans; Incidence; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tranexamic Acid; Ve | 2023 |
Thromboembolic Complications Following Perioperative Tranexamic Acid Administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Retrospective Studies; Tranexamic | 2024 |
Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation.
Topics: Adolescent; Adult; Extracorporeal Membrane Oxygenation; Hemorrhage; Hemostatics; Humans; Retrospecti | 2023 |
Comparison of the Effects of Intravenous and Oral Tranexamic Acid on Perioperative Hemoglobin Levels During Total Knee Arthroplasty.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Aged; Antifibrinolytic Agents; Arthro | 2020 |
Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2020 |
Tranexamic acid: So good it should be in the water?
Topics: Antifibrinolytic Agents; Humans; Tranexamic Acid; Venous Thromboembolism; Water | 2020 |
Does perioperative use of tranexamic acid in hip fracture patients increase the risk of venous thromboembolism and reduce the need for postoperative transfusions?
Topics: Antifibrinolytic Agents; Blood Transfusion; Hip Fractures; Humans; Retrospective Studies; Tranexamic | 2020 |
Venous thromboembolism after tranexamic acid administration: legitimate risk or statistical confounder?
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Tranexamic A | 2020 |
Randomized controlled trials and Cochrane analyses versus precision-based medicine for tranexamic acid and viscoelastic testing in trauma.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Fibrinolysis; Humans; Incidence; Precision Med | 2020 |
Outcomes of tranexamic acid administration in military trauma patients with intracranial hemorrhage: a cohort study.
Topics: Adult; Antifibrinolytic Agents; Disease Progression; Female; Glasgow Outcome Scale; Humans; Intracra | 2020 |
National trends in tranexamic acid use in the peripartum period, 2015-2019.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy; | 2020 |
Unjustified Administration in Liberal Use of Tranexamic Acid in Trauma Resuscitation.
Topics: Adult; Aged; Antifibrinolytic Agents; Female; Humans; Inappropriate Prescribing; Male; Middle Aged; | 2021 |
The incidence of venous thromboembolic events in trauma patients after tranexamic acid administration: an EAST multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Incidence; Male; Middle Aged; Retrospect | 2021 |
Tranexamic acid in patients with current or former cancer undergoing hip and knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Fema | 2021 |
Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss | 2021 |
Blood transfusion and venous thromboembolism trends and risk factors in primary and aseptic revision total hip and knee arthroplasties: A nationwide investigation of 736,061 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Humans; | 2022 |
Tranexamic acid is safe and effective in patients with heterozygous factor V Leiden mutation during total joint arthroplasty.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2023 |
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Topics: Anticoagulants; Female; Hemophilia A; Humans; Pregnancy; Tranexamic Acid; United Kingdom; Venous Thr | 2021 |
Tranexamic Acid is Associated With Decreasing the Risk of Complications in Patients Undergoing Arthroplasty With Preoperative Coagulopathy.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Human | 2021 |
Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events.
Topics: Abdominal Injuries; Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Guideline Adherence; | 2018 |
Does Tranexamic Acid Cause Venous Thromboembolism After Trauma?: Who Cares, If It Saves Lives?
Topics: Humans; Military Personnel; Tranexamic Acid; Venous Thromboembolism | 2018 |
How I treat heavy menstrual bleeding associated with anticoagulants.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Me | 2017 |
Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?
Topics: Antifibrinolytic Agents; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Humans; | 2018 |
Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Injury Severity Score | 2019 |
Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death After Total Hip Arthroplasty: A Population-Based Cohort Study from National Danish Databases.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Cardiovascular Diseases; Cohort Studi | 2018 |
Prehospital Tranexamic Acid Administration During Aeromedical Transport After Injury.
Topics: Adult; Air Ambulances; Antifibrinolytic Agents; Blood Transfusion; Emergency Service, Hospital; Fema | 2019 |
[Effect of tranexamic acid on blood loss and soft-tissue swelling following cemented total hip replacement].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Length of Sta | 2019 |
Optimal route for administering tranexamic acid in primary unilateral total hip arthroplasty: Results from a multicenter cohort study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Anticoagulants; Antifibrinolytic Agents; | 2019 |
Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Erythrocyte Tra | 2019 |
Does Tranexamic Acid Increase the Incidence of Thromboembolism After Spinal Fusion Surgery?
Topics: Aged; Female; Humans; Imaging, Three-Dimensional; Male; Postoperative Care; Spinal Fusion; Tomograph | 2020 |
Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bioma | 2014 |
Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bioma | 2014 |
Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bioma | 2014 |
Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bioma | 2014 |
Intra-articular injection of tranexamic acid to reduce blood loss after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Dose-Response Rel | 2014 |
Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2015 |
Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Cohort Studies; Female; Humans; Male; Pros | 2015 |
The Use of Intravenous Tranexamic Acid in Patients Undergoing Total Hip or Knee Arthroplasty: A Retrospective Analysis at a Single Military Institution.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2015 |
Impact of Tranexamic Acid in Total Knee and Total Hip Replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bloo | 2017 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Response to Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Topical Tranexamic Acid in Total Knee Arthroplasty Patients with Increased Thromboembolic Risk.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2017 |
Prevalence of Venous Thromboembolic Events Is Low in Asians After Total Knee Arthroplasty Without Chemoprophylaxis.
Topics: Aged; Arthroplasty, Replacement, Knee; Asian People; Chemoprevention; Female; Humans; Male; Middle A | 2017 |
Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthropl | 2017 |
The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Antifibrinolytic Agents; Databases, Factual; Epidemiolog | 2009 |
The routine use of tranexamic acid in hip and knee replacements.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biom | 2012 |